Neurocrine Biosciences, Inc. (NBIX)
USD 94.9
(4.43%)
USD 94.9
(4.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 177.3 Million USD | 0.0% |
| 2022 | - USD | -100.0% |
| 2021 | 99.6 Million USD | 125.62% |
| 2020 | -388.7 Million USD | -201.43% |
| 2019 | 383.22 Million USD | 55.29% |
| 2018 | 246.78 Million USD | 114.77% |
| 2017 | 114.9 Million USD | 238.0% |
| 2016 | -83.26 Million USD | -12.23% |
| 2015 | -74.19 Million USD | -139.23% |
| 2014 | -31.01 Million USD | 30.76% |
| 2013 | -44.78 Million USD | 29.75% |
| 2012 | -63.75 Million USD | -27.24% |
| 2011 | -50.1 Million USD | 7.3% |
| 2010 | -54.05 Million USD | -109.51% |
| 2009 | -25.79 Million USD | 62.32% |
| 2008 | -68.46 Million USD | 30.26% |
| 2007 | -98.17 Million USD | -259.1% |
| 2006 | -27.34 Million USD | -389.13% |
| 2005 | 9.45 Million USD | 85.45% |
| 2004 | 5.09 Million USD | 107.35% |
| 2003 | -69.42 Million USD | -90.83% |
| 2002 | -36.37 Million USD | 77.01% |
| 2001 | -158.2 Million USD | -819.35% |
| 2000 | -17.2 Million USD | 5.45% |
| 1999 | -18.2 Million USD | -109.2% |
| 1998 | -8.7 Million USD | 38.73% |
| 1997 | -14.2 Million USD | -46.39% |
| 1996 | -9.7 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 151.9 Million USD | 0.86% |
| 2024 Q1 | 150.6 Million USD | -15.06% |
| 2024 Q3 | -97.7 Million USD | -164.32% |
| 2023 Q2 | 98.6 Million USD | -71.85% |
| 2023 Q1 | 350.3 Million USD | 0.0% |
| 2023 Q3 | -37.9 Million USD | -138.44% |
| 2023 FY | 177.3 Million USD | 0.0% |
| 2023 Q4 | 177.3 Million USD | 567.81% |
| 2022 FY | - USD | -100.0% |
| 2022 Q2 | 105.3 Million USD | -49.86% |
| 2022 Q3 | 53.6 Million USD | -49.1% |
| 2022 Q1 | 210 Million USD | 110.84% |
| 2022 Q4 | - USD | -100.0% |
| 2021 Q3 | 126 Million USD | 87.22% |
| 2021 Q2 | 67.3 Million USD | -12.48% |
| 2021 Q1 | 76.9 Million USD | 119.78% |
| 2021 Q4 | 99.6 Million USD | -20.95% |
| 2021 FY | 99.6 Million USD | 125.62% |
| 2020 Q3 | -436.7 Million USD | -592.33% |
| 2020 Q1 | 312.7 Million USD | -18.4% |
| 2020 Q2 | 88.7 Million USD | -71.63% |
| 2020 FY | -388.7 Million USD | -201.43% |
| 2020 Q4 | -388.7 Million USD | 10.99% |
| 2019 Q3 | 311.43 Million USD | -3.78% |
| 2019 Q1 | 387.8 Million USD | 57.14% |
| 2019 Q4 | 383.22 Million USD | 23.05% |
| 2019 Q2 | 323.66 Million USD | -16.54% |
| 2019 FY | 383.22 Million USD | 55.29% |
| 2018 Q1 | 198.89 Million USD | 73.1% |
| 2018 FY | 246.78 Million USD | 114.77% |
| 2018 Q4 | 246.78 Million USD | 31.33% |
| 2018 Q3 | 187.91 Million USD | -11.55% |
| 2018 Q2 | 212.46 Million USD | 6.82% |
| 2017 FY | 114.9 Million USD | 238.0% |
| 2017 Q4 | 114.9 Million USD | 18.1% |
| 2017 Q3 | 97.29 Million USD | 90.09% |
| 2017 Q2 | 51.18 Million USD | 179.86% |
| 2017 Q1 | -64.08 Million USD | 23.03% |
| 2016 Q3 | -99.76 Million USD | -15.67% |
| 2016 Q4 | -83.26 Million USD | 16.53% |
| 2016 FY | -83.26 Million USD | -12.23% |
| 2016 Q2 | -86.24 Million USD | 25.2% |
| 2016 Q1 | -115.3 Million USD | -55.4% |
| 2015 Q1 | -170.26 Million USD | -448.98% |
| 2015 FY | -74.19 Million USD | -139.23% |
| 2015 Q2 | -132.07 Million USD | 22.43% |
| 2015 Q3 | -66.37 Million USD | 49.74% |
| 2015 Q4 | -74.19 Million USD | -11.78% |
| 2014 Q3 | -29.04 Million USD | 22.43% |
| 2014 Q4 | -31.01 Million USD | -6.78% |
| 2014 FY | -31.01 Million USD | 30.76% |
| 2014 Q1 | -105.53 Million USD | -135.62% |
| 2014 Q2 | -37.44 Million USD | 64.52% |
| 2013 FY | -44.78 Million USD | 29.75% |
| 2013 Q4 | -44.78 Million USD | -28.38% |
| 2013 Q1 | -31.55 Million USD | 50.51% |
| 2013 Q2 | -44.31 Million USD | -40.43% |
| 2013 Q3 | -34.88 Million USD | 21.27% |
| 2012 Q2 | -42.01 Million USD | 45.39% |
| 2012 FY | -63.75 Million USD | -27.24% |
| 2012 Q1 | -76.94 Million USD | -53.55% |
| 2012 Q4 | -63.75 Million USD | -43.31% |
| 2012 Q3 | -44.48 Million USD | -5.88% |
| 2011 Q3 | -39.51 Million USD | -109.77% |
| 2011 Q1 | -24.39 Million USD | 54.87% |
| 2011 FY | -50.1 Million USD | 7.3% |
| 2011 Q4 | -50.1 Million USD | -26.8% |
| 2011 Q2 | -18.83 Million USD | 22.77% |
| 2010 Q1 | -41.69 Million USD | -61.6% |
| 2010 FY | -54.05 Million USD | -109.51% |
| 2010 Q4 | -54.05 Million USD | 21.43% |
| 2010 Q3 | -68.79 Million USD | 19.61% |
| 2010 Q2 | -85.57 Million USD | -105.26% |
| 2009 Q3 | -18.04 Million USD | 11.79% |
| 2009 Q1 | -33.44 Million USD | 51.15% |
| 2009 Q2 | -20.45 Million USD | 38.86% |
| 2009 FY | -25.79 Million USD | 62.32% |
| 2009 Q4 | -25.79 Million USD | -43.01% |
| 2008 Q2 | -91.31 Million USD | 14.35% |
| 2008 Q3 | -79.84 Million USD | 12.56% |
| 2008 Q4 | -68.46 Million USD | 14.25% |
| 2008 FY | -68.46 Million USD | 30.26% |
| 2008 Q1 | -106.61 Million USD | -8.59% |
| 2007 Q2 | -281 Thousand USD | 98.92% |
| 2007 Q4 | -98.17 Million USD | -44324.43% |
| 2007 Q1 | -26.05 Million USD | 4.7% |
| 2007 FY | -98.17 Million USD | -259.1% |
| 2007 Q3 | -221 Thousand USD | 21.35% |
| 2006 Q2 | -29.71 Million USD | 31.75% |
| 2006 Q4 | -27.34 Million USD | -31.64% |
| 2006 FY | -27.34 Million USD | -389.13% |
| 2006 Q1 | -43.54 Million USD | -560.49% |
| 2006 Q3 | -20.76 Million USD | 30.11% |
| 2005 Q3 | -14.39 Million USD | -201.81% |
| 2005 Q4 | 9.45 Million USD | 165.71% |
| 2005 Q2 | 14.13 Million USD | -28.75% |
| 2005 Q1 | 19.83 Million USD | 289.06% |
| 2005 FY | 9.45 Million USD | 85.45% |
| 2004 Q1 | 9.12 Million USD | 113.14% |
| 2004 Q4 | 5.09 Million USD | 131.88% |
| 2004 Q3 | -15.99 Million USD | -144.26% |
| 2004 Q2 | 36.14 Million USD | 296.28% |
| 2004 FY | 5.09 Million USD | 107.35% |
| 2003 Q2 | -12.42 Million USD | 79.32% |
| 2003 Q3 | -101.29 Million USD | -714.97% |
| 2003 Q4 | -69.42 Million USD | 31.47% |
| 2003 FY | -69.42 Million USD | -90.83% |
| 2003 Q1 | -60.1 Million USD | -65.23% |
| 2002 Q3 | -49.93 Million USD | -18.15% |
| 2002 FY | -36.37 Million USD | 77.01% |
| 2002 Q4 | -36.37 Million USD | 27.15% |
| 2002 Q1 | -46.19 Million USD | 70.8% |
| 2002 Q2 | -42.26 Million USD | 8.52% |
| 2001 Q2 | -21.26 Million USD | 10.63% |
| 2001 Q4 | -158.2 Million USD | -1826.93% |
| 2001 Q3 | -8.21 Million USD | 61.4% |
| 2001 Q1 | -23.79 Million USD | -38.28% |
| 2001 FY | -158.2 Million USD | -819.35% |
| 2000 Q1 | -9.11 Million USD | 49.92% |
| 2000 Q2 | 161 Thousand USD | 101.77% |
| 2000 FY | -17.2 Million USD | 5.45% |
| 2000 Q3 | -8.1 Million USD | -5134.78% |
| 2000 Q4 | -17.2 Million USD | -112.29% |
| 1999 Q1 | -2.6 Million USD | 70.11% |
| 1999 FY | -18.2 Million USD | -109.2% |
| 1999 Q2 | -9.6 Million USD | -269.23% |
| 1999 Q3 | -4.5 Million USD | 53.13% |
| 1999 Q4 | -18.2 Million USD | -304.44% |
| 1998 FY | -8.7 Million USD | 38.73% |
| 1998 Q1 | -12.9 Million USD | 9.15% |
| 1998 Q4 | -8.7 Million USD | 43.51% |
| 1998 Q3 | -15.4 Million USD | -73.03% |
| 1998 Q2 | -8.9 Million USD | 31.01% |
| 1997 Q4 | -14.2 Million USD | -1.43% |
| 1997 Q3 | -14 Million USD | 35.48% |
| 1997 FY | -14.2 Million USD | -46.39% |
| 1997 Q2 | -21.7 Million USD | -261.67% |
| 1997 Q1 | -6 Million USD | 38.14% |
| 1996 FY | -9.7 Million USD | 0.0% |
| 1996 Q4 | -9.7 Million USD | -64.41% |
| 1996 Q1 | 2.2 Million USD | 0.0% |
| 1996 Q2 | -21.7 Million USD | -1086.36% |
| 1996 Q3 | -5.9 Million USD | 72.81% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -9526.85% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -136.558% |
| Journey Medical Corporation | -9.7 Million USD | 1926.141% |
| Embecta Corp. | 1.31 Billion USD | 86.486% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 61.347% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 59.029% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 1234.02% |
| Alpha Teknova, Inc. | 1.97 Million USD | -8881.763% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -88.203% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 59.273% |
| Cosmos Health Inc. | 8.59 Million USD | -1963.846% |
| Dynavax Technologies Corporation | 106.63 Million USD | -66.268% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 235.52% |
| PainReform Ltd. | -7.95 Million USD | 2330.189% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 1234.02% |
| SCYNEXIS, Inc. | -19.35 Million USD | 1016.279% |
| Safety Shot Inc | -2.28 Million USD | 7861.423% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 1980.223% |
| Procaps Group, S.A. | 242.93 Million USD | 27.017% |
| Theratechnologies Inc. | 24.87 Million USD | -612.878% |
| Harrow Health, Inc. | 116.41 Million USD | -52.297% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 7135.714% |
| Biofrontera Inc. | 4.05 Million USD | -4271.302% |
| DURECT Corporation | -7.65 Million USD | 2416.436% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 628.828% |
| Cronos Group Inc. | -663.32 Million USD | 126.729% |
| OptiNose, Inc. | 58.06 Million USD | -205.347% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 71.558% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 1316.717% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 3518.799% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -1080.976% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 2887.891% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -165819.576% |
| Radius Health, Inc. | 359.28 Million USD | 50.651% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -89804.619% |
| ProPhase Labs, Inc. | 19.23 Million USD | -821.949% |
| Phibro Animal Health Corporation | 454.84 Million USD | 61.02% |
| Procaps Group S.A. | 242.93 Million USD | 27.017% |
| Alvotech | 1.06 Billion USD | 83.341% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -4720.555% |
| Viatris Inc. | 17.13 Billion USD | 98.965% |
| Rockwell Medical, Inc. | 4.45 Million USD | -3878.905% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 3735.432% |
| SIGA Technologies, Inc. | -148.68 Million USD | 219.248% |
| Tilray Brands, Inc. | 158.97 Million USD | -11.526% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | -45.449% |
| Shineco, Inc. | 29.29 Million USD | -505.32% |
| PetIQ, Inc. | 351.93 Million USD | 49.621% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 6210.784% |
| Incannex Healthcare Limited | -5.48 Million USD | 3332.452% |
| Alimera Sciences, Inc. | 55.3 Million USD | -220.563% |
| Silver Spike Investment Corp. | -32.61 Million USD | 643.671% |
| Assertio Holdings, Inc. | -32.52 Million USD | 645.052% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 12009.544% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 3603.687% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 3783.008% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 2258.647% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -4104.411% |
| Hempacco Co., Inc. | 13.61 Million USD | -1202.271% |
| Talphera, Inc. | -5.72 Million USD | 3199.109% |
| Alvotech | 1.06 Billion USD | 83.341% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -2381.456% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 283.332% |
| Currenc Group, Inc. | -16.57 Million USD | 1169.804% |
| Kamada Ltd. | -46.43 Million USD | 481.853% |
| Indivior PLC | -33.95 Million USD | 622.208% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -67942.092% |
| Flora Growth Corp. | -713 Thousand USD | 24966.76% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 2258.647% |
| Evolus, Inc. | 63.7 Million USD | -178.301% |
| HUTCHMED (China) Limited | -197.45 Million USD | 189.791% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 62.994% |
| Akanda Corp. | 3.9 Million USD | -4440.431% |